The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety

The low cost of thiazolidinediones makes them a potentially valuable therapeutic option for the  > 300 million economically disadvantaged persons worldwide with type 2 diabetes mellitus. Differential selectivit...

Source: Cardiovascular Diabetology - February 25, 2020 Category: Cardiology Authors: Charles E. Leonard, Colleen M. Brensinger, Ghadeer K. Dawwas, Rajat Deo, Warren B. Bilker, Samantha E. Soprano, Neil Dhopeshwarkar, James H. Flory, Zachary T. Bloomgarden, Joshua J. Gagne, Christina L. Aquilante, Stephen E. Kimmel and Sean Hennessy Tags: Original investigation Source Type: research